Abstract
Craniofacial defect is a critical problem in dental clinic, which has a tremendous impact on patients’ quality of life. Mesenchymal stem cell-based therapy has emerged as a promising approach for tissue defect repair. However, reduced survival after mesenchymal stem cells (MSCs) transplantation remains as a major problem in this area, which hampers the outcome of regeneration. Recently, the mechanism to mobilize endogenous MSCs for tissue regeneration has received increasing attentions, as it does not require exogenous cell transplantation. The primary goal of this study was to confirm the role of intravenous substance P in mobilizing endogenous CD45−CD11b−CD29+ MSCs in critical-sized bone defect animals and to investigate the effects of substance P on calvarial bone repair. Flow cytometry analyses revealed that intravenous substance P promoted the mobilization of endogenous CD45−CD11b−CD29+ MSCs after bone defect. In addition, Micro-CT showed that intravenous substance P improved the outcomes of calvarial bone repair. Furthermore, we discovered that systemic injection of substance P attenuated inflammation and enhanced the survival of the local-transplanted GFP+ MSCs. Our findings suggested that substance P together with its mobilized CD45−CD11b−CD29+ MSCs helped improve calvarial defect repair through regulating inflammatory conditions and promoting the survival of local-transplanted cells.
Highlights
Researchers have found that endogenous mesenchymal stem cells (MSCs) can provide a novel source for defect repair and may overcome the above limitations[1,6,7,8]
Researchers have demonstrated that substance P, as an injury-inducible messenger, can act early in the wound healing process and mobilize CD45−CD11b−CD29+ MSCs from bone marrow into peripheral circulation using corneal injury model[12]
The absolute numbers of CD45−CD11b−CD29+ cells in peripheral blood from the other three groups were significantly higher than that of the uninjured group (Fig. 1a,b) (P < 0.01). This indicated that both calvarial injury and i.v.substance P could promote the enrichment of CD45−CD11b−CD29+ cells in peripheral blood
Summary
Researchers have found that endogenous MSCs can provide a novel source for defect repair and may overcome the above limitations[1,6,7,8]. These endogenous MSCs are present in multiple adult tissues and can be recruited to the injury site after stimulation[10,11]. Researchers have demonstrated that substance P, as an injury-inducible messenger, can act early in the wound healing process and mobilize CD45−CD11b−CD29+ MSCs from bone marrow into peripheral circulation using corneal injury model[12]. Our study indicated the potential role of systemic-injected substance P in regulating inflammation during bone healing process
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
